Trials / Recruiting
RecruitingNCT06166888
A Study of AK131 in Patients With Advanced Solid Tumors
A Phase Ia/Ib, Multicenter and Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Anti-PD-1 and CD73 Bispecific Antibody AK131 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase Ia/Ib study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK131 in advanced solid tumor patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK131 | AK131 is an anti-PD-1 and CD73 bispecific antibody |
Timeline
- Start date
- 2024-01-10
- Primary completion
- 2026-08-01
- Completion
- 2028-12-01
- First posted
- 2023-12-12
- Last updated
- 2024-01-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06166888. Inclusion in this directory is not an endorsement.